

# Triscend CAS

<b><u>INVESTIGATORS</u></b>	<ul style="list-style-type: none"><li>• Robert Cubeddu, MD-Principal Investigator</li><li>• Mazen Albaghdadi, MD -Sub Investigator</li><li>• Luis Paz, MD-Sub Investigator</li><li>• Brian Solomon, MD Sub-Investigator</li><li>• Viviana Navas, MD Sub-Investigator</li><li>• David Axline, MD Sub-Investigator</li><li>• Hany Elmahdy, MD Sub-Investigator</li></ul>
<b><u>Trial Objective</u></b>	<ul style="list-style-type: none"><li>• The objectives of this global pivotal clinical trial are to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system with OMT compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation</li></ul>
<b><u>Randomization</u></b>	<ul style="list-style-type: none"><li>• All patient meeting Inclusion Exclusion receive EVOQUE tricuspid valve replacement system treatment</li></ul>
<b><u>Key Inclusion</u></b>	<ul style="list-style-type: none"><li>• Functional and/ or Degenerative TR graded as at least severe on TTE</li></ul>
<b><u>Key Exclusion</u></b>	<ul style="list-style-type: none"><li>• LVEF&lt;25%</li><li>• Evidence of severe right ventricular dysfunction</li><li>• Severe aortic, mitral, and or pulmonic valve stenosis and/or regurgitation</li></ul>